Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 39.6% | 7% | 5.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 37.8% | 36.5% | 40.7% | 35.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -12.4% | -26.4% | -16.6% | -28% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.5% | -30.9% | -20.7% | -26% |
| EPS Diluted | -0.32 | -0.76 | -0.63 | -0.63 |
| % Growth | 57.9% | -20.6% | 0% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | $0 |